Allena Pharma Stock Under Pressure After Equity Raise Of $28M

  • Allena Pharmaceuticals Inc ALNA has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311.
  • With gross proceeds of $28 million, the offering will close by July 16.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The warrants have an exercise price of $1.25 per share, are exercisable immediately, and have a term of five years.
  • The Company intends to use the proceeds for working capital and general corporate purposes. 
  • Earlier this week, the Company provided updates on its ALLN-346 and reloxaliase (ALLN-177) clinical programs.
  • For reloxaliase, it preponed interim analysis to 1Q of 2022 from 2Q/3Q of 2022.
  • It is on track to report initial results from Phase 2a of ALLN-346 by the end of 2021.
  • Price Action: ALNA shares are down 18.75 at $1.13 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingOfferingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!